Physician profile
Christopher Eric Henson
NPI 1871688697
$17,130.21
in general payments reported to CMS, 2019-2025
36 companies · $1,404 in 2025
The $1,404 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,948 · 2020: $2,103 · 2021: $3,665 · 2022: $2,288 · 2023: $2,214 · 2024: $2,509 · 2025: $1,404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,126.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,347.13 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $2,145.30 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $1,685.73 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Allergan, INC. | $1,556.53 | 2019-2021 | |
| Abbvie INC. | $1,519.71 | 2021-2025 | |
| Lilly USA, LLC | $1,511.85 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Amgen INC. | $825.72 | 2019-2024 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $823.43 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $614.99 | 2021-2025 | |
| Abbott Laboratories | $555.04 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $524.22 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $342.86 | 2019-2022 | |
| Dexcom, INC. | $226.20 | 2022-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $184.57 | 2020-2025 | |
| Phathom Pharmaceuticals, INC. | $183.93 | 2024-2025 | Voquezna |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Henson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.